Loading
A phase 3 trial of Trastuzumab deruxtecan in metastatic cancer, run by Daiichi Sankyo, now recruiting.
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) is a phase 3 interventional study registered as NCT06174987 by Daiichi Sankyo, with 50 participants planned, started 2024-01-05 and due to reach its primary completion in 2026-08-03. Interventions recorded: T-DXd. Conditions listed: Advanced Cancer, Metastatic Cancer. No results are recorded here; the registry entry is the source.
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Metastatic cancer (cancer that has spread).
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC).